ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The most common adverse reactions are:oTreatment-Naive Adults (>=5%): headache, arthralgia, fatigue, nausea, dizziness, abdominal pain, pruritus, flushing, vomiting, urticaria (6.1).oPatients who Switched from Imiglucerase, after Months on Treatment (>=10%): arthralgia, headache, pain in extremity (6.1).To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. oTreatment-Naive Adults (>=5%): headache, arthralgia, fatigue, nausea, dizziness, abdominal pain, pruritus, flushing, vomiting, urticaria (6.1).. oPatients who Switched from Imiglucerase, after Months on Treatment (>=10%): arthralgia, headache, pain in extremity (6.1).. 6.1Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Adverse Reactions from Clinical Trials of ELELYSO as Initial TherapyoClinical Trial in Adult Patients The safety of ELELYSO at dosages of either 30 units/kg (n=16) (50% of the recommended dosage) [see Dosage and Administration (2.1)] or 60 units/kg (n=16) administered intravenously every other week was assessed in 32 adult treatment-naive patients (aged 19 to 74 years) with Type Gaucher disease in 9-month double-blind, randomized clinical trial (Trial 1) [see Clinical Studies (14)]. Table presents the adverse reactions that occurred in these ELELYSO-treated patients.Table 1:Adverse Reactions in >=5% of Treatment-Naive Adult Patients Treated with ELELYSOPreferred TermTreatment-Naive Adults (N=32)n (%)Headache6 (19)Arthralgia4 (13)Fatigue3 (9)Nausea3 (9)Dizziness3 (9)Abdominal pain2 (6)Pruritus2 (6)Flushing2 (6)Vomiting2 (6)Urticaria2 (6)oClinical Trial in Pediatric Patients 16 Years of Age and Younger The safety of ELELYSO at dosages of either 30 units/kg (n=4) (50% of the recommended dosage) [see Dosage and Administration (2.1)] or 60 units/kg (n=5) administered intravenously every other week was assessed in pediatric treatment-naive patients (aged to 13 years) with Type Gaucher disease in 12-month randomized clinical trial (Trial 2) [see Clinical Studies (14)]. The most common adverse reaction (>=10%) was vomiting, which occurred in of patients. Two patients developed hypersensitivity reactions; patient experienced severe vomiting and gastrointestinal inflammation, and experienced mild throat irritation and chest discomfort. Both patients responded to treatment with antihistamines and continued ELELYSO treatment.Adverse Reactions in Clinical Trial in Patients Who Switched from Imiglucerase to ELELYSOThe safety of ELELYSO was assessed in 31 patients (26 adult and pediatric patients), ages to 66 years old, with Type Gaucher disease who had previously been receiving imiglucerase treatment for minimum of years (Trial 3). ELELYSO was administered intravenously every other week for months at the same number of units as each patients previous imiglucerase dose. Table presents the adverse reactions in these ELELYSO-treated patients.Table 2: Adverse Reactions in >=10% of ELELYSO-Treated Patients Who Switched from Imiglucerase to ELELYSO (after months on treatment)Preferred TermAdult and Pediatric Patients Switched from Imiglucerase(N=31)n (%)Arthralgia4 (13)Headache4 (13)Pain in extremity3 (10)Immunogenicity: Anti-Drug Antibody-Associated Adverse Reactions Trials 1, 2, and evaluated ELELYSO enzyme replacement therapy (ERT)-naive and ERT-experienced adult and pediatric patients with Gaucher disease [see Clinical Studies (14.1, 14.2)]. In patients with Type Gaucher disease, hypersensitivity reactions occurred in 36% (9/25) of ELELYSO-treated patients who developed ADA during the treatment period and in 15% (6/41) of ELELYSO-treated patients who did not develop ADA during the treatment period [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.6)]. Of the ELELYSO-treated patients who tested positive for ADA and who developed hypersensitivity reactions, patients had anaphylaxis and additional patient discontinued ELELYSO due to hypersensitivity reactions.. oClinical Trial in Adult Patients. The safety of ELELYSO at dosages of either 30 units/kg (n=16) (50% of the recommended dosage) [see Dosage and Administration (2.1)] or 60 units/kg (n=16) administered intravenously every other week was assessed in 32 adult treatment-naive patients (aged 19 to 74 years) with Type Gaucher disease in 9-month double-blind, randomized clinical trial (Trial 1) [see Clinical Studies (14)]. Table presents the adverse reactions that occurred in these ELELYSO-treated patients.. oClinical Trial in Pediatric Patients 16 Years of Age and Younger The safety of ELELYSO at dosages of either 30 units/kg (n=4) (50% of the recommended dosage) [see Dosage and Administration (2.1)] or 60 units/kg (n=5) administered intravenously every other week was assessed in pediatric treatment-naive patients (aged to 13 years) with Type Gaucher disease in 12-month randomized clinical trial (Trial 2) [see Clinical Studies (14)].. 6.2Postmarketing Experience. The following adverse reactions have been identified during post-approval use of ELELYSO. Because these reactions include those reported voluntarily from population of uncertain size in addition to those from postmarketing studies, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure:oGastrointestinal disorders: Vomiting, diarrheaoGeneral disorders and administration site conditions: FatigueoImmune system disorders: Anaphylaxis [see Warnings and Precautions (5.1)], Type III immune mediated fixed drug eruptionoMusculoskeletal and connective tissue disorders: Back pain. oGastrointestinal disorders: Vomiting, diarrhea. oGeneral disorders and administration site conditions: Fatigue. oImmune system disorders: Anaphylaxis [see Warnings and Precautions (5.1)], Type III immune mediated fixed drug eruption. oMusculoskeletal and connective tissue disorders: Back pain.

MECHANISM OF ACTION SECTION.

12.1 Mechanism of Action. Gaucher disease is an autosomal recessive disorder caused by mutations in the human glucocerebrosidase gene, which results in reduced activity of the lysosomal enzyme glucocerebrosidase. Glucocerebrosidase catalyzes the conversion of the sphingolipid glucocerebroside into glucose and ceramide. The enzymatic deficiency results in accumulation of substrate glucocerebroside primarily in the lysosomal compartment of macrophages, giving rise to foam cells or Gaucher cells, which accumulate in the liver, spleen and bone marrow.ELELYSO, an enzyme replacement therapy, is recombinant analog of human lysosomal glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, reducing the amount of accumulated glucocerebroside. ELELYSO uptake into cellular lysosomes is mediated by binding of ELELYSO mannose oligosaccharide chains to specific mannose receptors on the cell surface leading to internalization and subsequent transport to the lysosomes.

NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term studies in animals to evaluate carcinogenic potential or studies to evaluate mutagenic potential have not been performed with taliglucerase alfa. In male and female fertility study in rats, taliglucerase alfa did not cause any significant adverse effect on male or female fertility parameters up to maximum dose of 55 mg/kg/day (about times the recommended human dose of 60 units/kg based on the body surface area).

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PRINCIPAL DISPLAY PANEL 200 unit Vial Label. NDC 0069-0106-01PfizerElelyso(R) (taliglucerase alfa)for injection200 units/vialFor intravenous infusion onlySingle-Dose Vial. Discardany unused portion. Rx only PRINCIPAL DISPLAY PANEL 200 unit Vial Label.

PEDIATRIC USE SECTION.

8.4 Pediatric Use. The safety and effectiveness of ELELYSO for the treatment of pediatric patients years of age and older with confirmed diagnosis of Type Gaucher disease has been established. The use of ELELYSO for this indication is supported by evidence of effectiveness from adequate and well-controlled trials of ELELYSO in adults, with additional pharmacodynamic data from pediatric patients and pharmacokinetic data from pediatric patients who participated in clinical trials [see Clinical Studies (14.1, 14.2) and Clinical Pharmacology (12.3)]. Data from 14 pediatric patients were included in the safety evaluation [see Adverse Reactions (6.1)]. The safety and effectiveness of ELELYSO has not been established in patients less than years of age.Pediatric patients experienced higher frequency of vomiting during ELELYSO treatment (4 of treatment-naive patients) than adult patients, and this may be symptom of hypersensitivity reaction. The frequencies of other adverse reactions were similar between pediatric and adult patients treated with ELELYSO [see Adverse Reactions (6.1)].

BOXED WARNING SECTION.

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.Initiate ELELYSO in healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue ELELYSO and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1)].. WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS See full prescribing information for complete boxed warning.oAnaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. (5.1)oInitiate ELELYSO in healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. (5.1)oIf severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue ELELYSO and immediately initiate appropriate medical treatment, including use of epinephrine. (5.1). oAnaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. (5.1). oInitiate ELELYSO in healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. (5.1). oIf severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue ELELYSO and immediately initiate appropriate medical treatment, including use of epinephrine. (5.1).

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term studies in animals to evaluate carcinogenic potential or studies to evaluate mutagenic potential have not been performed with taliglucerase alfa. In male and female fertility study in rats, taliglucerase alfa did not cause any significant adverse effect on male or female fertility parameters up to maximum dose of 55 mg/kg/day (about times the recommended human dose of 60 units/kg based on the body surface area).

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Gaucher disease is an autosomal recessive disorder caused by mutations in the human glucocerebrosidase gene, which results in reduced activity of the lysosomal enzyme glucocerebrosidase. Glucocerebrosidase catalyzes the conversion of the sphingolipid glucocerebroside into glucose and ceramide. The enzymatic deficiency results in accumulation of substrate glucocerebroside primarily in the lysosomal compartment of macrophages, giving rise to foam cells or Gaucher cells, which accumulate in the liver, spleen and bone marrow.ELELYSO, an enzyme replacement therapy, is recombinant analog of human lysosomal glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, reducing the amount of accumulated glucocerebroside. ELELYSO uptake into cellular lysosomes is mediated by binding of ELELYSO mannose oligosaccharide chains to specific mannose receptors on the cell surface leading to internalization and subsequent transport to the lysosomes.. 12.3 Pharmacokinetics. Pharmacokinetics of taliglucerase alfa were evaluated in 38 patients (29 adult and pediatric patients) who received intravenous infusions of ELELYSO 30 units/kg (50% of the recommended dosage) or 60 units/kg (the recommended dosage) [see Dosage and Administration (2.1)] every other week. The pharmacokinetic parameters in adult and pediatric patients are summarized in Table 3.In adult Type Gaucher disease patients treated with ELELYSO 30 units/kg (50% of the recommended dosage) or 60 units/kg (the recommended dosage) [see Dosage and Administration (2.1)] (N=29) every other week as initial therapy, pharmacokinetics were determined with the first dose and at Week 38 of treatment. The pharmacokinetics of taliglucerase alfa appeared to be nonlinear with greater than dose-proportional increase in exposure at the doses studied. No significant accumulation or change in taliglucerase alfa pharmacokinetics over time from Weeks to 38 was observed with repeated dosages of 30 units/kg (50% of the recommended dosage) or 60 units/kg (the recommended dosage) [see Dosage and Administration (2.1)] every other week. Based on the limited data, there were no significant pharmacokinetic differences between male and female patients in this study.The pharmacokinetics of taliglucerase alfa were evaluated in pediatric patients to 17 years of age with Type Gaucher disease who were treated with ELELYSO for 10 to 27 months. Six of the patients were treatment-naive, and patients were switched from imiglucerase. In both the 30 units/kg (50% of the recommended dosage) and 60 units/kg (the recommended dosage) [see Dosage and Administration (2.1)] dose groups, clearance values in pediatric patients were similar to those in adult patients. AUC values in pediatric patients were lower than AUC values in adult patients, due to weight-based dosing of taliglucerase alfa and lower body weights in pediatric patients.Table 3:Taliglucerase Alfa Pharmacokinetic Parameters after Repeated Dosing in Adult and Pediatric Patients with Type Gaucher DiseasePediatric Patients (N=9)Median (Range)Adult Patients at Week 38 (N=29)Median (Range)30 units/kg30 units/kg is 50% of the recommended dose.n=560 units/kgn=430 units/kgn=1460 units/kgn=15Age (years)15 (10, 17)11 (4, 16)35 (19, 74)33 (19, 58)Weight (kg)44.3 (22.8, 71.0)28.6 (16.5, 50.4)72.5 (51.5, 99.5)73.5 (58.5, 87.0)n=14 AUC0- (ngh/mL)Values were derived from concentration data expressed in ng/mL 1416 (535, 1969)2984 (1606, 4273)2007 (1007, 10092)6459 (2548, 21020) T1/2 (min)37.1 (22.5, 56.8)32.5 (18.0, 42.9)18.9 (9.20, 57.9)28.7 (11.3, 104) CL (L/h)30.5 (17.4, 37.8)15.8 (11.7, 24.9)30.5 (6.79, 68.0)18.5 (6.20, 37.9) Vss (L)14.9 (10.1, 35.6)8.80 (3.75, 21.4)11.7 (2.3, 22.7)10.7 (1.4, 18.5) 12.6Immunogenicity. The observed incidence of ADA (including neutralizing antibodies [Nab]) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of ELELYSO or of other taliglucerase alfa products.. Anti-Drug AntibodiesIn Trials 1, 2, and 3, greater portion of ELELYSO-treated patients who developed ADA had hypersensitivity reactions compared to those who did not develop ADA [see Adverse Reactions (6.1) and Warnings and Precautions (5.1)].In Trial (treatment-naive adults with Gaucher disease) [see Clinical Studies (14.1)], 17 (53%) of 32 ELELYSO-treated patients developed ADA. Additionally (6%) patients tested positive for ADA at baseline prior to ELELYSO treatment. In Trial (treatment-naive pediatric patients with Gaucher disease) [see Clinical Studies (14.1)], (22%) of Type Gaucher disease ELELYSO-treated patients developed ADA. Additionally, patient was ADA-positive prior to initiation of ELELYSO. In Trial (switched from imiglucerase to ELELYSO), of 31 ELELYSO-treated patients (26 adult and pediatric patients) [see Clinical Studies (14.2)], adults (23% of adult patients) developed ADA and no pediatric patient developed ADA. Additionally, (10%) patients were ADA positive prior to initiation of ELELYSO. There is insufficient information to characterize the ADA response to ELELYSO and the effects of ADA on pharmacokinetics, pharmacodynamics, or effectiveness of taliglucerase alfa products.Neutralizing AntibodiesIn Trials 1, and with total number of 72 patients, 30 of the 31 ELELYSO-treated adult and pediatric patients who developed ADA or tested positive for ADA at baseline were evaluated for neutralizing activity of the ADA in the mannose receptor binding and enzyme activity assays. oNineteen (63%) of the 30 patients had neutralizing antibodies (Nab) capable of inhibiting in vitro mannose receptor binding of ELELYSO. oEight (42%) of these 19 patients had Nab capable of inhibiting the in vitro enzymatic activity of ELELYSO. Although the effectiveness was numerically lower (less spleen and liver volume reduction) in ELELYSO-treated patients who developed Nab compared to those that did not develop Nab, the data were not sufficient to fully assess whether the observed Nab reduces effectiveness.Other AntibodiesNine (29%) of the 31 ELELYSO-treated adult and pediatric patients who developed ADA during treatment or tested positive for ADA at baseline also developed antibodies against plant-specific glycans in ELELYSO.. oNineteen (63%) of the 30 patients had neutralizing antibodies (Nab) capable of inhibiting in vitro mannose receptor binding of ELELYSO. oEight (42%) of these 19 patients had Nab capable of inhibiting the in vitro enzymatic activity of ELELYSO.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. 14.1Clinical Trials of ELELYSO as Initial Therapy Clinical Trial in Adult PatientsThe safety and efficacy of ELELYSO in the treatment of adult patients with Type Gaucher disease was assessed in 9-month, multi-center, double-blind, randomized trial (Trial 1) in 31 adult patients with Gaucher disease-related enlarged spleens (>8 times normal) and thrombocytopenia (<120,000 /mm3). Sixteen patients had enlarged livers and 10 patients had anemia at baseline. All patients were naive to enzyme replacement therapy (ERT). Patients with severe neurological symptoms were excluded from the trial. Patients were randomized to receive ELELYSO at an intravenous dosage of either 30 units/kg (n=15) (50% of the recommended dosage) or 60 units/kg (the recommended dosage) [see Dosage and Administration (2.1)] (n=16) every other week. After months, 26 of the 31 patients continued in the blinded portion of the long-term extension trial for total treatment duration of 24 months at the same intravenous dosage every other week. Twenty-three of those 26 patients continued open-label ELELYSO treatment (30 or 60 units/kg given intravenously every other week) for an additional 12 months (total duration of ELELYSO treatment was 36 months). Baseline Demographics In Trial 1, patients were 19 to 74 years of age (mean age 36 years), 48% were male, 97% were White and 29% and 71% were Hispanic/Latino and non Hispanic/Latino, respectively.Efficacy ResultsTable shows the baseline values and mean (SD) changes in clinical parameters (spleen volume, liver volume, platelet count, and hemoglobin) after months of ELELYSO treatment in Trial 1. Liver and spleen volumes were measured by MRI and are reported as percentage of body weight (%BW) and multiples of normal (MN). The observed reduction from baseline in spleen volume (the primary endpoint), was considered to be clinically meaningful in light of the natural history of untreated Gaucher disease.Table 4: Mean (SDSD standard deviation) Changes in Clinical Parameters from Baseline to Months in Treatment-Naive Adults with Type Gaucher Disease Treated with ELELYSO (N=31) (Trial 1)Clinical ParameterELELYSO30 units/kgThe recommended ELELYSO dosage in treatment-naive adult patients is 60 units/kg every other week. ELELYSO 30 units/kg every other week is not recommended dosage. [see Dosage and Administration (2.1)] (n=15)Mean (SD)ELELYSO60 units/kg (n=16)Mean (SD)Spleen Volume (%BW%BW percentage of body weight)Baseline3.1 (1.5)3.3 (2.7)Month 92.2 (1.3)2.1 (1.9)Change-0.9 (0.4)-1.3 (1.1)Spleen Volume (MNMN multiples of normal)Baseline15.4 (7.7)16.7 (13.4)Month 911.1 (6.3)10.4 (9.4)Change-4.5 (2.1)-6.6 (5.4)Liver Volume (%BW)Baseline4.2 (0.9)3.8 (1.0)Month 93.6 (0.7)3.1 (0.7)Change-0.6 (0.5)-0.6 (0.4)Liver Volume (MN)Baseline1.7 (0.4)1.5 (0.4)Month 91.4 (0.3)1.2 (0.3)Change-0.2 (0.2)-0.3 (0.2)Platelet Count (mm3)Baseline75,320 (40,861)65,038 (28,668)Month 986,747 (50,989)106,531 (53,212)Change11,427 (20,214)41,494 (47,063)Hemoglobin (g/dl)Baseline12.2 (1.7)11.4 (2.6)Month 914.0 (1.4)13.6 (2.0)Change1.6 (1.4)2.2 (1.4)The following data are the changes in clinical parameters from baseline to Month 24 (including the 9-month initial period and the 15-month first long-term extension) for the 30 units/kg (n=12) (50% of the recommended dosage) and 60 units/kg (the recommended dosage) [see Dosage and Administration (2.1)] (n=14) treatment groups, respectively: mean (SD) spleen volume (%BW) decreased by 1.4 (0.6) and 2.0 (2.0), in MN by 6.8 (3.0) and 10.2 (9.8); hemoglobin increased by 1.3 (1.7) g/dL and 2.4 (2.3) g/dL; liver volume (%BW) decreased by 1.1 (0.5) and 1.0 (0.7), in MN by 0.4 (0.2) and 0.4 (0.3 and platelet count increased 28,433 (31,996)/mm3 and 72,029 (68,157)/mm3. The 23 patients who continued open-label ELELYSO treatment for additional 12 months demonstrated stability in these clinical parameters.. Clinical Trial in Pediatric Patients 16 Years of Age and YoungerThe safety and efficacy of ELELYSO in the treatment of pediatric patients with Type Gaucher disease was assessed in 12-month, multi-center, double-blind, randomized trial (Trial 2) in treatment-naive patients. Patients were randomized to receive ELELYSO at an intravenous dosage of either 30 units/kg (n=4) (50% of the recommended dosage) or 60 units/kg (the recommended dosage) [see Dosage and Administration (2.1)] (n=5) every other week. After 12 months, all patients entered blinded portion of the long-term extension trial (24 months of total treatment) where they continued treatment with ELELYSO at the same dosage every other week. Baseline DemographicsIn Trial 2, patients were to 13 years of age (mean age 8.1 years), 67% were male, 89% were White and 44% and 56% were Hispanic/Latino and non Hispanic/Latino, respectively.Efficacy ResultsThe following data in Trial are the changes [median (Q1, Q3)] in clinical parameters from baseline to Month 12 for the 60 units/kg dose group (n=5): spleen volume decreased from 18.4 (14.2, 35.1) MN to 11.0 (8.3, 14.5) MN; hemoglobin increased from 11.1 (9.2, 11.3) g/dL to 11.7 (11.5, 12.9) g/dL; liver volume decreased from 2.1 (2.0, 2.3) MN to 1.6 (1.5, 1.9) MN; platelet count increased from 80,000 (79,000, 87,000)/mm3 to 131,000 (119,000, 215,000)/mm3.The following data are the changes [median (Q1, Q3)] in clinical parameters from baseline to Month 24 (including the initial 12-month period and the 12-month long-term extension) for the 60 units/kg dose group (n=5): spleen volume decreased by 19.0 (8.3, 41.2) MN; hemoglobin increased by 2.5 (1.9, 3.0) g/dL; liver volume decreased by 0.8 (0.6, 1.1) MN; and platelet count increased by 76,000 (67,000, 100,000)/mm3.. 14.2Clinical Trial in Patients Switching from Imiglucerase Treatment to ELELYSO. The safety and efficacy of ELELYSO were assessed in 31 patients (26 adult and pediatric patients) with Type Gaucher disease who were switched from imiglucerase to ELELYSO (Trial 3). Trial was 9-month, multi-center, open-label, single arm study in patients who had been receiving intravenous treatment with imiglucerase at dosages ranging from 9.5 units/kg to 60 units/kg every other week for minimum of years. Patients were required to be clinically stable and have stable biweekly dosage of imiglucerase for at least months prior to enrollment. Imiglucerase therapy was stopped, and treatment with ELELYSO was administered every other week at the same number of units as each patients previous imiglucerase dose (9.5 units/kg to 60 units/kg given intravenously every other week). If needed, adjustment of dosage was allowed during the study in order to maintain stability of clinical parameters (i.e., spleen volume, liver volume, platelet count, and hemoglobin). oEighteen of the 26 adult patients who completed the 9-month clinical trial continued treatment with ELELYSO (9.5 units/kg to 60 units/kg given intravenously every other week) in an open-label extension trial for additional 27 months (total duration of ELELYSO treatment was 36 months). oFive of the pediatric patients who completed the 9-month trial continued open-label treatment with ELELYSO (9.5 units/kg to 60 units/kg given intravenously every other week) for additional 24 months (total duration of ELELYSO treatment was 33 months).Baseline DemographicsIn Trial 3, patients were to 66 years of age (mean age 42 years, including pediatric patients), 55% were male, 97% were White, and 16% and 84% were Hispanic/Latino and non Hispanic/Latino, respectively.Efficacy ResultsIn Trial 3, at baseline, spleen volume was 5.2 (4.5) MN, liver volume was 1.0 (0.3) MN, platelet count was 161,137 (73,387)/mm3, and hemoglobin was 13.5 (1.4) g/dL. Mean (SD) organ volumes and hematologic values remained stable through months of ELELYSO treatment. After months of ELELYSO treatment, spleen volume was 4.8 (4.6) MN, liver volume was 1.0 (0.2) MN, platelet count was 161,167 (80,820)/mm3, and hemoglobin was 13.4 (1.5) g/dL. The ELELYSO dosage remained unchanged in 30 of 31 patients. One patient required dose increase at Week 24 (from 9.5 units/kg to 19 units/kg) for platelet count of 92,000/mm3 at Week 22, which subsequently increased to 170,000/mm3 at Month 9.During the 36-month period, 18 ELELYSO-treated adult patients maintained stability in clinical parameters (spleen volume, liver volume, platelet count and hemoglobin); however only 10 of 18 adult patients completed 27 months of ELELYSO treatment in the extension trial and only patients had their spleen and liver volumes assessed at 36 months.During the 33-month period, the ELELYSO-treated pediatric patients demonstrated stability in these clinical parameters.. oEighteen of the 26 adult patients who completed the 9-month clinical trial continued treatment with ELELYSO (9.5 units/kg to 60 units/kg given intravenously every other week) in an open-label extension trial for additional 27 months (total duration of ELELYSO treatment was 36 months). oFive of the pediatric patients who completed the 9-month trial continued open-label treatment with ELELYSO (9.5 units/kg to 60 units/kg given intravenously every other week) for additional 24 months (total duration of ELELYSO treatment was 33 months).

CONTRAINDICATIONS SECTION.

4 CONTRAINDICATIONS. None.. None (4).

DESCRIPTION SECTION.

11 DESCRIPTION. Taliglucerase alfa is hydrolytic lysosomal glucocerebroside-specific enzyme produced by recombinant DNA technology using plant cell culture (carrot). Taliglucerase alfa is monomeric glycoprotein enzyme containing N-linked glycosylation sites (kDa=60.8). Taliglucerase alfa differs from native human glucocerebrosidase by amino acids at the terminal and up to amino acids at the terminal. Taliglucerase alfa is glycosylated protein with oligosaccharide chains at the glycosylation sites having terminal mannose sugars. These mannose-terminated oligosaccharide chains of taliglucerase alfa are specifically recognized by endocytic carbohydrate receptors on macrophages, the cells that accumulate lipid in Gaucher disease.A unit is the amount of enzyme that catalyzes the hydrolysis of micromole of the synthetic substrate para-nitrophenyl--D-glucopyranoside (pNP-Glc) per minute at 37 C.ELELYSO (taliglucerase alfa) for injection is supplied as sterile, preservative-free, lyophilized powder for reconstitution and dilution prior to intravenous infusion. Each single-dose vial contains 200 units of taliglucerase alfa and D-mannitol (206.7 mg), polysorbate 80 (0.56 mg), and sodium citrate (30.4 mg). Citric acid may be added to adjust the pH at the time of manufacture. After reconstitution with 5.1 mL Sterile Water for Injection, USP, taliglucerase alfa concentration is 40 units/mL [see Dosage and Administration (2)]. Reconstituted solutions have pH of approximately 6.0.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. Recommendations Prior to ELELYSO Treatment (2.1):oAdministration of ELELYSO should be supervised by healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis.Recommended Dosage in Patients Years and Older (2.2):oTreatment-naive: 60 units/kg administered every other week as 60- to 120-minute intravenous infusion.oPatients switching from imiglucerase: Initiate ELELYSO intravenous treatment (60- to 120-minute infusion) with the same units/kg imiglucerase dosage and subsequently administer ELELYSO every other week. Dosage adjustments can be based on achievement and maintenance of each patients therapeutic goals.Preparation and Administration (2.3, 2.4, 2.5):oReconstitute, dilute and administer under the supervision of healthcare professional.oSee Full Prescribing Information for complete instructions. oAdministration of ELELYSO should be supervised by healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis.. oTreatment-naive: 60 units/kg administered every other week as 60- to 120-minute intravenous infusion.. oPatients switching from imiglucerase: Initiate ELELYSO intravenous treatment (60- to 120-minute infusion) with the same units/kg imiglucerase dosage and subsequently administer ELELYSO every other week. Dosage adjustments can be based on achievement and maintenance of each patients therapeutic goals.. oReconstitute, dilute and administer under the supervision of healthcare professional.. oSee Full Prescribing Information for complete instructions. 2.1Recommendations Prior to ELELYSO Treatment Administration of ELELYSO should be supervised by healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis [see Warnings and Precautions (5.1)].Initiate ELELYSO in healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment [see Warnings and Precautions (5.1)].To reduce the risk of hypersensitivity reactions, consider pretreatment with antihistamines and/or corticosteroids [see Warnings and Precautions (5.1)].. 2.2Recommended Dosage in Patients Years and Older. Treatment-Naive Patients Years of Age and OlderThe recommended dosage of ELELYSO is 60 units/kg (based on actual body weight) administered every other week as 60- to 120-minute intravenous infusion.. Patients Years of Age and Older Switching from ImigluceraseIf it is acceptable to switch from stable imiglucerase dosage to ELELYSO, initiate ELELYSO intravenous treatment (60- to 120-minute infusion) with the same units/kg imiglucerase dosage and subsequently administer ELELYSO every other week. Dosage adjustments can be made based on achievement and maintenance of each patients therapeutic goals. 2.3Preparation Instructions. ELELYSO should be reconstituted, diluted, and administered under the supervision of healthcare professional.Prepare ELELYSO according to the following steps using aseptic technique:a.Determine the number of vials to be reconstituted based on the patients weight in kg and the recommended dose [see Dosage and Administration (2.2)]. Round the number of vials up to the next whole number.b.Remove the required number of vials from the refrigerator. Do not leave these vials at room temperature longer than 24 hours prior to reconstitution. Do not heat or microwave these vials.c.Reconstitute each vial of ELELYSO with 5.1 mL of Sterile Water for Injection, USP to yield reconstituted product with concentration of 40 units/mL and an extractable volume of mL. (1)Upon reconstitution, mix vials gently. DO NOT SHAKE. (2)Prior to further dilution, visually inspect the reconstituted solution in the vials for particulate matter and discoloration. The solution should be clear and colorless. Discard if particulate matter is present or the solution is discolored.d.Withdraw the calculated dose of drug from the appropriate number of vials and dilute with 0.9% Sodium Chloride Injection, USP, to final volume of 100 to 200 mL. Discard any unused reconstituted solution.(1)For pediatric patients years of age and older, use final volume of 100 to 120 mL.(2)For adult patients, may use final volume of 130 to 150 mL. However, if the volume of reconstituted product alone is equal to or greater than 130 to 150 mL, then the final volume should not exceed 200 mL.e.Mix the diluted solution gently. DO NOT SHAKE. Since this is protein solution, slight flocculation (described as translucent fibers) occurs occasionally after dilution.f.Discard any unused diluted solution.. a.Determine the number of vials to be reconstituted based on the patients weight in kg and the recommended dose [see Dosage and Administration (2.2)]. Round the number of vials up to the next whole number.. b.Remove the required number of vials from the refrigerator. Do not leave these vials at room temperature longer than 24 hours prior to reconstitution. Do not heat or microwave these vials.. c.Reconstitute each vial of ELELYSO with 5.1 mL of Sterile Water for Injection, USP to yield reconstituted product with concentration of 40 units/mL and an extractable volume of mL. (1)Upon reconstitution, mix vials gently. DO NOT SHAKE. (2)Prior to further dilution, visually inspect the reconstituted solution in the vials for particulate matter and discoloration. The solution should be clear and colorless. Discard if particulate matter is present or the solution is discolored.. (1)Upon reconstitution, mix vials gently. DO NOT SHAKE. (2)Prior to further dilution, visually inspect the reconstituted solution in the vials for particulate matter and discoloration. The solution should be clear and colorless. Discard if particulate matter is present or the solution is discolored.. d.Withdraw the calculated dose of drug from the appropriate number of vials and dilute with 0.9% Sodium Chloride Injection, USP, to final volume of 100 to 200 mL. Discard any unused reconstituted solution.(1)For pediatric patients years of age and older, use final volume of 100 to 120 mL.(2)For adult patients, may use final volume of 130 to 150 mL. However, if the volume of reconstituted product alone is equal to or greater than 130 to 150 mL, then the final volume should not exceed 200 mL.. (1)For pediatric patients years of age and older, use final volume of 100 to 120 mL.. (2)For adult patients, may use final volume of 130 to 150 mL. However, if the volume of reconstituted product alone is equal to or greater than 130 to 150 mL, then the final volume should not exceed 200 mL.. e.Mix the diluted solution gently. DO NOT SHAKE. Since this is protein solution, slight flocculation (described as translucent fibers) occurs occasionally after dilution.. f.Discard any unused diluted solution.. 2.4Storage and Handling of the Reconstituted and Diluted Solution oIf the reconstituted ELELYSO vial is not used immediately, refrigerate at C to C (36 to 46 F) for up to 24 hours (under protection from light) or store at controlled room temperature at 20 to 25 (68 to 77 F) for up to hours (without protection from light). oIf the diluted solution is not administered immediately, refrigerate at C to C (36 to 46 F) for up to 24 hours (under protection from light). oThe total storage time for the reconstituted and diluted solution should not exceed 24 hours. Discard the unused reconstituted or diluted solution after 24 hours from the start of preparation. oDo not freeze.. oIf the reconstituted ELELYSO vial is not used immediately, refrigerate at C to C (36 to 46 F) for up to 24 hours (under protection from light) or store at controlled room temperature at 20 to 25 (68 to 77 F) for up to hours (without protection from light). oIf the diluted solution is not administered immediately, refrigerate at C to C (36 to 46 F) for up to 24 hours (under protection from light). oThe total storage time for the reconstituted and diluted solution should not exceed 24 hours. Discard the unused reconstituted or diluted solution after 24 hours from the start of preparation. oDo not freeze.. 2.5Administration Instructions. After reconstitution and dilution, administer via intravenous infusion over minimum of 60 minutes and with an in-line low protein-binding 0.2 micron filter.oFor pediatric patients who weigh (based on actual body weight):oLess than 30 kg use an infusion rate of mL/minute. oGreater than or equal to 30 kg, use an initial infusion rate of mL/minute. After tolerability to ELELYSO is established, may increase the infusion rate to maximum of mL/minute. oFor adult patients, use an initial infusion rate of 1.2 mL/minute. After tolerability to ELELYSO is established, may increase the infusion rate to maximum of 2.2 mL/minute.. oFor pediatric patients who weigh (based on actual body weight):oLess than 30 kg use an infusion rate of mL/minute. oGreater than or equal to 30 kg, use an initial infusion rate of mL/minute. After tolerability to ELELYSO is established, may increase the infusion rate to maximum of mL/minute. oLess than 30 kg use an infusion rate of mL/minute. oGreater than or equal to 30 kg, use an initial infusion rate of mL/minute. After tolerability to ELELYSO is established, may increase the infusion rate to maximum of mL/minute. oFor adult patients, use an initial infusion rate of 1.2 mL/minute. After tolerability to ELELYSO is established, may increase the infusion rate to maximum of 2.2 mL/minute.

DOSAGE FORMS & STRENGTHS SECTION.

3 DOSAGE FORMS AND STRENGTHS. For injection: 200 units white to off-white lyophilized powder in single-dose vial for reconstitution.. For injection: 200 units lyophilized powder in single-dose vial for reconstitution (3).

GERIATRIC USE SECTION.

8.5 Geriatric Use. During clinical trials, patients aged 65 or older were treated with ELELYSO. Clinical trials of ELELYSO did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

HOW SUPPLIED SECTION.

16 HOW SUPPLIED/STORAGE AND HANDLING. ELELYSO (taliglucerase alfa) for injection is supplied as sterile, preservative-free, white to off-white lyophilized powder in single-dose vial. Each vial of ELELYSO contains 200 units of taliglucerase alfa.Each carton contains one vial (NDC 0069-0106-01).. Refrigerate ELELYSO at C to C (36 to 46 F) in the original carton to protect from light. Do not freeze.

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE. ELELYSO is indicated for the treatment of patients years of age and older with confirmed diagnosis of Type Gaucher disease. ELELYSO is hydrolytic lysosomal glucocerebroside-specific enzyme indicated for the treatment of patients years and older with confirmed diagnosis of Type Gaucher disease (1).

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. Hypersensitivity Reactions Including AnaphylaxisAdvise patients and caregivers that life-threatening hypersensitivity reactions, including anaphylaxis may occur with ELELYSO treatment.Advise patients and caregivers that anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.Inform patients and caregivers of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1)].This products labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.

LACTATION SECTION.

8.2 Lactation. Risk SummaryThere are no data on the presence of taliglucerase alfa in human milk or the effects of taliglucerase alfa on milk production. Lactation data from product registry have not identified adverse reactions in infants exposed to taliglucerase alfa during breastfeeding. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for ELELYSO and any potential adverse effects on the breastfed child from ELELYSO or from the underlying maternal condition.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. Pharmacokinetics of taliglucerase alfa were evaluated in 38 patients (29 adult and pediatric patients) who received intravenous infusions of ELELYSO 30 units/kg (50% of the recommended dosage) or 60 units/kg (the recommended dosage) [see Dosage and Administration (2.1)] every other week. The pharmacokinetic parameters in adult and pediatric patients are summarized in Table 3.In adult Type Gaucher disease patients treated with ELELYSO 30 units/kg (50% of the recommended dosage) or 60 units/kg (the recommended dosage) [see Dosage and Administration (2.1)] (N=29) every other week as initial therapy, pharmacokinetics were determined with the first dose and at Week 38 of treatment. The pharmacokinetics of taliglucerase alfa appeared to be nonlinear with greater than dose-proportional increase in exposure at the doses studied. No significant accumulation or change in taliglucerase alfa pharmacokinetics over time from Weeks to 38 was observed with repeated dosages of 30 units/kg (50% of the recommended dosage) or 60 units/kg (the recommended dosage) [see Dosage and Administration (2.1)] every other week. Based on the limited data, there were no significant pharmacokinetic differences between male and female patients in this study.The pharmacokinetics of taliglucerase alfa were evaluated in pediatric patients to 17 years of age with Type Gaucher disease who were treated with ELELYSO for 10 to 27 months. Six of the patients were treatment-naive, and patients were switched from imiglucerase. In both the 30 units/kg (50% of the recommended dosage) and 60 units/kg (the recommended dosage) [see Dosage and Administration (2.1)] dose groups, clearance values in pediatric patients were similar to those in adult patients. AUC values in pediatric patients were lower than AUC values in adult patients, due to weight-based dosing of taliglucerase alfa and lower body weights in pediatric patients.Table 3:Taliglucerase Alfa Pharmacokinetic Parameters after Repeated Dosing in Adult and Pediatric Patients with Type Gaucher DiseasePediatric Patients (N=9)Median (Range)Adult Patients at Week 38 (N=29)Median (Range)30 units/kg30 units/kg is 50% of the recommended dose.n=560 units/kgn=430 units/kgn=1460 units/kgn=15Age (years)15 (10, 17)11 (4, 16)35 (19, 74)33 (19, 58)Weight (kg)44.3 (22.8, 71.0)28.6 (16.5, 50.4)72.5 (51.5, 99.5)73.5 (58.5, 87.0)n=14 AUC0- (ngh/mL)Values were derived from concentration data expressed in ng/mL 1416 (535, 1969)2984 (1606, 4273)2007 (1007, 10092)6459 (2548, 21020) T1/2 (min)37.1 (22.5, 56.8)32.5 (18.0, 42.9)18.9 (9.20, 57.9)28.7 (11.3, 104) CL (L/h)30.5 (17.4, 37.8)15.8 (11.7, 24.9)30.5 (6.79, 68.0)18.5 (6.20, 37.9) Vss (L)14.9 (10.1, 35.6)8.80 (3.75, 21.4)11.7 (2.3, 22.7)10.7 (1.4, 18.5).

PREGNANCY SECTION.

8.1 Pregnancy. Risk SummaryAvailable data, including data from product registry and pharmacovigilance reports, have not identified drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes in pregnant women exposed to ELELYSO. Additionally, there are risks associated with untreated symptomatic Type Gaucher disease in pregnant women (see Clinical Considerations ). In animal reproduction studies when pregnant rats and rabbits were administered taliglucerase alfa at intravenous doses up to times the recommended human dose (RHD), there was no evidence of embryo-fetal toxicity (see Data ).The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively.. Clinical Considerations. Disease-Associated Maternal and/or Embryo/Fetal RiskWomen with Type Gaucher disease have an increased risk of spontaneous abortion if disease symptoms are not treated and controlled pre-conception and during pregnancy. Pregnancy may exacerbate existing Type Gaucher disease symptoms or result in new disease manifestations. Type Gaucher disease manifestations may lead to adverse pregnancy outcomes, including hepatosplenomegaly which can interfere with the normal growth of fetus and thrombocytopenia which can lead to increased bleeding and possible postpartum hemorrhage requiring transfusion.. Data. Animal DataReproduction studies have been performed with taliglucerase alfa administered during the period of organogenesis in rats and rabbits. In rats, intravenous doses up to 55 mg/kg/day (about times the RHD of 60 units/kg based on the body surface area) did not cause any adverse effects on embryo-fetal development. In rabbits, intravenous doses up to 27.8 mg/kg/day (about times the RHD of 60 units/kg based on the body surface area) did not show any embryo-fetal toxicity.

RECENT MAJOR CHANGES SECTION.

Warnings and Precautions (5.1)1/2025.

SPL UNCLASSIFIED SECTION.

2.1Recommendations Prior to ELELYSO Treatment Administration of ELELYSO should be supervised by healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis [see Warnings and Precautions (5.1)].Initiate ELELYSO in healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment [see Warnings and Precautions (5.1)].To reduce the risk of hypersensitivity reactions, consider pretreatment with antihistamines and/or corticosteroids [see Warnings and Precautions (5.1)].

STORAGE AND HANDLING SECTION.

Refrigerate ELELYSO at C to C (36 to 46 F) in the original carton to protect from light. Do not freeze.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy. Risk SummaryAvailable data, including data from product registry and pharmacovigilance reports, have not identified drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes in pregnant women exposed to ELELYSO. Additionally, there are risks associated with untreated symptomatic Type Gaucher disease in pregnant women (see Clinical Considerations ). In animal reproduction studies when pregnant rats and rabbits were administered taliglucerase alfa at intravenous doses up to times the recommended human dose (RHD), there was no evidence of embryo-fetal toxicity (see Data ).The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively.. Clinical Considerations. Disease-Associated Maternal and/or Embryo/Fetal RiskWomen with Type Gaucher disease have an increased risk of spontaneous abortion if disease symptoms are not treated and controlled pre-conception and during pregnancy. Pregnancy may exacerbate existing Type Gaucher disease symptoms or result in new disease manifestations. Type Gaucher disease manifestations may lead to adverse pregnancy outcomes, including hepatosplenomegaly which can interfere with the normal growth of fetus and thrombocytopenia which can lead to increased bleeding and possible postpartum hemorrhage requiring transfusion.. Data. Animal DataReproduction studies have been performed with taliglucerase alfa administered during the period of organogenesis in rats and rabbits. In rats, intravenous doses up to 55 mg/kg/day (about times the RHD of 60 units/kg based on the body surface area) did not cause any adverse effects on embryo-fetal development. In rabbits, intravenous doses up to 27.8 mg/kg/day (about times the RHD of 60 units/kg based on the body surface area) did not show any embryo-fetal toxicity.. 8.2 Lactation. Risk SummaryThere are no data on the presence of taliglucerase alfa in human milk or the effects of taliglucerase alfa on milk production. Lactation data from product registry have not identified adverse reactions in infants exposed to taliglucerase alfa during breastfeeding. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for ELELYSO and any potential adverse effects on the breastfed child from ELELYSO or from the underlying maternal condition.. 8.4 Pediatric Use. The safety and effectiveness of ELELYSO for the treatment of pediatric patients years of age and older with confirmed diagnosis of Type Gaucher disease has been established. The use of ELELYSO for this indication is supported by evidence of effectiveness from adequate and well-controlled trials of ELELYSO in adults, with additional pharmacodynamic data from pediatric patients and pharmacokinetic data from pediatric patients who participated in clinical trials [see Clinical Studies (14.1, 14.2) and Clinical Pharmacology (12.3)]. Data from 14 pediatric patients were included in the safety evaluation [see Adverse Reactions (6.1)]. The safety and effectiveness of ELELYSO has not been established in patients less than years of age.Pediatric patients experienced higher frequency of vomiting during ELELYSO treatment (4 of treatment-naive patients) than adult patients, and this may be symptom of hypersensitivity reaction. The frequencies of other adverse reactions were similar between pediatric and adult patients treated with ELELYSO [see Adverse Reactions (6.1)].. 8.5 Geriatric Use. During clinical trials, patients aged 65 or older were treated with ELELYSO. Clinical trials of ELELYSO did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. See boxed warning (5.1). 5.1Hypersensitivity Reactions Including Anaphylaxis. Life-threatening hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with enzyme replacement therapies, including ELELYSO. In clinical trials, (patients were not routinely pretreated with antihistamines and/or corticosteroids prior to ELELYSO infusions during the clinical trials):o2 of 72 (3%) ELELYSO-treated patients experienced signs and symptoms consistent with anaphylaxis including urticaria, hypotension, flushing, wheezing, chest tightness, nausea, vomiting, and dizziness. These reactions occurred during ELELYSO infusion.o21 of 72 (29%) ELELYSO-treated patients experienced hypersensitivity reactions, including the ELELYSO-treated patients who experienced signs and symptoms consistent with anaphylaxis. Signs and symptoms of these hypersensitivity reactions included pruritus, angioedema, flushing, erythema, rash, nausea, vomiting, cough, chest tightness, and throat irritation. These reactions occurred during ELELYSO infusion and up to hours after the start of infusion [see Adverse Reactions (6.1)].Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Administration of ELELYSO should be supervised by healthcare provider knowledgeable in the management of hypersensitivity reactions including anaphylaxis. Initiate ELELYSO in healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. Observe patients closely during and after the infusion.ELELYSO-treated patients who developed anti-taliglucerase alfa antibodies (referred to as anti-drug antibodies (ADA)) generally had greater frequency of hypersensitivity reactions compared to those who did not develop ADA [see Adverse Reactions (6.1)]. Closely monitor for hypersensitivity reactions in patients who develop ADA.Management of hypersensitivity reactions should be based on the severity of the reaction and includes slowing or temporary interruption of the infusion and/or administration of antihistamines, antipyretics, and/or corticosteroids for mild reactions. To reduce the risk of hypersensitivity reactions, consider pretreatment with antihistamines and/or corticosteroids. If severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue ELELYSO and immediately initiate appropriate medical treatment, including use of epinephrine.Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur.Consider the risks and benefits of re-administering ELELYSO in patients who have experienced severe hypersensitivity reaction associated with ELELYSO. Caution should be exercised upon rechallenge [see Adverse Reactions (6.2) ]. o2 of 72 (3%) ELELYSO-treated patients experienced signs and symptoms consistent with anaphylaxis including urticaria, hypotension, flushing, wheezing, chest tightness, nausea, vomiting, and dizziness. These reactions occurred during ELELYSO infusion.. o21 of 72 (29%) ELELYSO-treated patients experienced hypersensitivity reactions, including the ELELYSO-treated patients who experienced signs and symptoms consistent with anaphylaxis. Signs and symptoms of these hypersensitivity reactions included pruritus, angioedema, flushing, erythema, rash, nausea, vomiting, cough, chest tightness, and throat irritation. These reactions occurred during ELELYSO infusion and up to hours after the start of infusion [see Adverse Reactions (6.1)].